A185490 Stock Overview
Engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EyeGene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,860.00 |
| 52 Week High | ₩4,895.00 |
| 52 Week Low | ₩2,430.00 |
| Beta | 1.54 |
| 11 Month Change | 2.51% |
| 3 Month Change | -21.21% |
| 1 Year Change | -4.35% |
| 33 Year Change | -84.50% |
| 5 Year Change | -65.85% |
| Change since IPO | -73.80% |
Recent News & Updates
Shareholder Returns
| A185490 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.4% | -8.1% | 2.9% |
| 1Y | -4.3% | 18.1% | -2.8% |
Return vs Industry: A185490 underperformed the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A185490 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A185490 volatility | |
|---|---|
| A185490 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A185490 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A185490's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 47 | Won-Il Yoo | www.eyegene.co.kr |
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company’s products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster.
EyeGene Inc. Fundamentals Summary
| A185490 fundamental statistics | |
|---|---|
| Market cap | ₩77.31b |
| Earnings (TTM) | -₩12.34b |
| Revenue (TTM) | ₩2.84b |
27.2x
P/S Ratio-6.3x
P/E RatioIs A185490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A185490 income statement (TTM) | |
|---|---|
| Revenue | ₩2.84b |
| Cost of Revenue | ₩1.13b |
| Gross Profit | ₩1.71b |
| Other Expenses | ₩14.05b |
| Earnings | -₩12.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -456.35 |
| Gross Margin | 60.20% |
| Net Profit Margin | -434.22% |
| Debt/Equity Ratio | 5.4% |
How did A185490 perform over the long term?
See historical performance and comparison